摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,4-triazolo<4,3-a>pyridin-3(2H)-one sodium salt

中文名称
——
中文别名
——
英文名称
1,2,4-triazolo<4,3-a>pyridin-3(2H)-one sodium salt
英文别名
sodium [1,2,4]triazolo[4,3-a]pyridin-3(2H)-one;1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one,sodium salt;sodium;[1,2,4]triazolo[4,3-a]pyridin-3-olate
1,2,4-triazolo<4,3-a>pyridin-3(2H)-one sodium salt化学式
CAS
——
化学式
C6H4N3O*Na
mdl
——
分子量
157.107
InChiKey
DHJVUTOGWXCZHU-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.34
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    33.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-(3-氯苯基)-4-(3-氯丙基)哌嗪盐酸盐1,2,4-triazolo<4,3-a>pyridin-3(2H)-one sodium salt四丁基溴化铵sodium carbonate 作用下, 以 异丙醇 为溶剂, 反应 12.0h, 以83%的产率得到盐酸曲唑酮
    参考文献:
    名称:
    [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF TRAZODONE AND HYDROCHLORIDE SALT THEREOF
    [FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION DE TRAZODONE ET SON SEL DE CHLORHYDRATE
    摘要:
    本发明提供了一种改进的制备几乎纯曲唑酮及其盐酸盐的过程。该过程包括将化合物-Π(如所述)与化合物-III(如所述)在无机碱和催化剂的存在下反应;在该过程中,曲唑酮游离碱和/或其盐酸盐通过在较低温度下沉淀而得到。制备曲唑酮盐酸盐(化合物I)的改进过程将烷基化物(如本文所述)的总量作为杂质控制在不到10ppm。制备曲唑酮盐酸盐(化合物I)的改进过程将1-(3-氯苯基)-4-(3-氯丙基)哌嗪的总量作为杂质控制在不到2.5ppm。
    公开号:
    WO2015110883A1
  • 作为产物:
    参考文献:
    名称:
    MORROW, D. F.
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Treatment of sleeping disorders using CNS sleep target modulators
    申请人:Hypnion, Inc.
    公开号:US20030232839A1
    公开(公告)日:2003-12-18
    The invention is directed to compositions used for treating sleep disorders. In addition, the invention provides convenient methods of treatment of a sleep disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of ester derivatized trazodone compounds for the treatment of sleep disorders.
    该发明涉及用于治疗睡眠障碍的组合物。此外,该发明提供了治疗睡眠障碍的方便方法。此外,该发明提供了使用在特定时间段内保持活性以减少副作用的组合物治疗睡眠障碍的方法。更具体地,该发明涉及酯衍生的曲唑酮化合物的组合物和用途,用于治疗睡眠障碍。
  • Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5HT<sub>2A</sub> and α<sub>1</sub> Receptor Binding Affinity
    作者:Marilena Giannangeli、Nicola Cazzolla、Maria Rita Luparini、Maurizio Magnani、Massimo Mabilia、Giuseppe Picconi、Mauro Tomaselli、Leandro Baiocchi
    DOI:10.1021/jm970700n
    日期:1999.2.1
    A series of triazolopyridine derivatives (compounds 2a-I) were synthesized in order to-explore the effect of modifications of the alkylpiperazine moiety of trazodone (fragment A) on binding affinity for 5HT(2A) and alpha(1) receptors. All of the synthesized compounds show a decrease of affinity for both 5HT(2A) and alpha(1) receptors, as compared to trazodone, with the exception of compounds 2b,c which bear a methyl group in an alpha position to the aliphatic nitrogen atom N-1. These compounds showed a decrease of affinity only for the alpha(1) receptor. The stereochemical influence of the piperazine moiety of compound 2c was also evaluated. Enantiomer (S)-2c showed the most significant differences between 5HT(2A) and alpha(1) receptor affinity (IC50 values) and among the corresponding functional properties (pA(2) values). Since (S)-2c cannot generate the metabolite 4-(3-chlorophenyl)piperazine this product was selected for further pharmacological studies.
查看更多